CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with

the United States Postal Service as first-class an envelope addressed

Commissioner for Patents, P.O. Box 1450,

April 13, 2005

(Date)

AnneMarie Kaiser, Reg. No. 37,649

Alexandria, VA 22313-1450, on

in

Docket No.: GNE.3230R1C22



INFORMATION DISCLOSURE STATEMENT

policant

Goddard, et al. (as amended)

App. No

10/063,532

Filed

May 2, 2002

For

A POLYPEPTIDE ENCODED BY A

NUCLEIC ACID OVEREXPRESSED

IN KIDNEY TUMOR AND

UNDEREXPRESSED IN LUNG

TUMOR

Examiner

Jegatheesan Seharaseyon

Art Unit

1647

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is an Information Disclosure Statement by Applicant (PTO/SB/08 equivalent) listing 28 references to be considered by the Examiner. Also enclosed are 15 foreign patent references and/or non-patent literature as listed on the Information Disclosure Statement.

This Information Disclosure Statement is being filed within three months of the filing date, with an RCE or before receipt of a first office action after an RCE and no fee is required.

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

By:

AnneMarie Kaiser

Registration No. 37,649

Attorney of Record Customer No. 30,313

(619) 235-8550

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Application No. 10/063,532

Filing Date May 2, 2002

First Named Inventor Goddard, et al. (as amended)

Art Unit 1647

Examiner Jegatheesan Seharaseyon

Attorney Docket No. GNE.3230R1C22

Multiple sheets used when necessary)
SHEET 1 OF 2

PK 1 5 2000	9									
U.S. PATENT DOCUMENTS										
TEMANELLA Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear					
	1	6,025,156	02-15-2000	Gwynn, et al.						
	2	6,124,433	09-26-2000	Falb, et al.						
	3	6,156,500	12-05-2000	Falb, Dean						
	4	6,162,604	12-19-2000	Jacob, Chaim O.						
	5	6,228,582	05-08-2001	Rodier, et al.						
	6	6,395,306	05-28-2002	Cui, et al.						
	7	6,414,117	07-02-2002	Levinson, D. A.						
	8	6,465,185	10-15-2002	Goldfine, et al.						
	9	6,498,235	12-24-2002	Sheppard, et al.						
	10	6,562,343	05-13-2003	Levinson, D. A.						
	11	6,645,499	11-11-2003	Lal, et al.	,					
	12	6,730,502	05-04-2004	Van Hijum, et al.						
	13	6,737,522	05-18-2004	Sundick, et al.						

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹			
·	14	ALBERTS, et al. 1994. <i>Molecular Biology of the Cell, 3rd Edition</i> , pp. 403-404, 453. New York: Garland Publishing.				
	15	ALBERTS, et al. 2002. <i>Molecular Biology of the Cell 4th Edition</i> , pp. 302, 363-364, 379, 435. New York: Garland Publishing.				
	16	GRIMALDI, et al. 1989. The t(5;14) chromosomal translocation in a case of acute lymphocytic leukemia joins the interleukin-3 gene to the immunoglobulin heavy chain gene. <i>Blood</i> , 73(8):2081-2085.				
	17	GYGI, et al. Mar. 1999. Correlation between Protein and mRNA Abundance in Yeast. Molecular and Cellular Biology, 1720-1730.				
	18	HANNA, et al. Aug. 1999. HER-2/neu breast cancer predictive testing. <i>Pathology Associates Medical Laboratories</i> .				
	19	HYMAN et al. Nov. 2002. Impact of DNA Amplification of Gene Expression Patterns. Cancer Research, 62:6240-6245.				
	20	LEWIN, B. 1994. Oncogenes: Gene Expression and Cancer, Chap. 39, pp.1196-1201. Genes V. New York: Oxford University Press.				

Examiner Signature Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Application No. 10/063,532

Filing Date May 2, 2002

First Named Inventor Goddard, et al. (as amended)

Art Unit 1647

Examiner Jegatheesan Seharaseyon

Attorney Docket No. GNE.3230R1C22

Multiple sheets used when necessary)
SHEET 2 OF 2

IPK 7 5 2005	1 21				
NON PATENT LITERATURE DOCUMENTS					
Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹		
	21	LEWIN, B. 1997. Regulation of Transcription, Chap. 29, pp. 847-848. <i>Genes VI</i> . New York: Oxford University Press.			
	22	MEEKER, et al. 1990. Activation of the interleukin-3 gene by chromosome translocation in acute lymphocytic leukemia with eosinophilia. <i>Blood</i> , 76(2):285-289.			
	23	MERIC, et al. 2002. Translation initiation in cancer: A novel target for therapy. <i>Molecular Cancer Therapeutics</i> , 1:971-979.			
	24	ØRNTOFT, et al. 2002. Genome-wide study of gene copy numbers, transcripts, and protein levels in pairs of non-invasive and invasive human transitional cell carcinomas. <i>Molecular & Cellular Proteomics</i> , 1:37-45.			
	25	POLLACK, et al. 2002. Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. <i>PNAS</i> , 99(20):12963-12968.			
	26	SINGLETON, et al. 1992. Clinical and pathologic significance of the c- <i>erb</i> B-2 (<i>HER-2/neu</i>) oncogene. <i>Pathol. Annu</i> , 1(27):165-190.			
	27	ZHIGANG, et al. 2004. Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues and its potential role in prostate carcinogenesis and progression of prostate cancer. World Journal of Surgical Oncology, 2:13.			
_	28	2002-2003 Catalog & Technical Reference, New England BioLabs, Inc., p. 122.			

1609543 041305

Examiner Signature

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.